Leprosy Mailing List – December 4, 2025
Ref.: (LML) Announcement new LRI calls for proposals - Budget Round 2027
From: LRI, Amsterdam, the Netherlands
Dear colleagues,
The Leprosy Research Initiative (LRI) is pleased to announce two calls for proposals for funding commencing in 2027; the LRI Flagship grant and the RESILIENTD grant.
The deadline for submission for both calls is Friday January 23, 2026 at 17:00 CET, so make sure to submit your Letter of Intent timely.
The LRI Flagship call returns and is now open for research proposal submissions. This call offers an excellent opportunity for innovative, high-impact research that advances the understanding, prevention, and management of leprosy, including studies that address leprosy alongside other neglected tropical diseases (NTDs) or conditions with cross-cutting challenges.
In this round, preference will be given to applications focusing on reactions and nerve function impairment, while proposals addressing all other LRI research priorities are also welcome.
RESILIENTD grant
In collaboration with our partner, Anesvad Foundation, the RESILIENTD grant is now open for its third round of applications. This funding focuses on addressing the social determinants of health in the context of skin NTDs, including leprosy, with a particular emphasis on sub-Saharan Africa.
Leprosy Research Initiative
Wibautstraat 137k
Amsterdam, NH 1097 DN
Netherlands
info@leprosyresearch.org
________________________________________________________________________________
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/4201cbe1-8dae-4a32-bdf7-0a85482e67fdn%40googlegroups.com.
No comments:
Post a Comment